Table I.
Number of patients with positive patch tests (+ or ++) to carpet extracts and identified allergens
| Total patients (n=31) | Eczema (n=26) | Urticaria or rhinitis only no eczema (n=5) | Control group (n=47) | |
|---|---|---|---|---|
| Carpet 1 100% | 0 | 0 | 0 | – |
| Carpet 1 10% | 1 | 1 | 0 | – |
| Carpet 1 with glue 100% | 10 | 8 | 2 | 2 |
| Carpet 1 with glue 10% | 0 | 0 | 0 | – |
| Carpet 2 100% | 0 | 0 | 0 | – |
| Carpet 2 10% | 0 | 0 | 0 | – |
| Carpet 3 100% | 1 | 1 | 0 | – |
| Carpet 3 10% | 0 | 0 | 0 | – |
| Carpet 4 100% | 5 | 4 | 1 | 1 |
| Carpet 4 10% | 0 | 0 | 0 | – |
| BIT 0.05% pet | 0 | 0 | 0 | – |
| MI/MCI 0.020% aq | 0 | 0 | 0 | – |
| MI 0.20% aq | 0 | 0 | 0 | – |
| DEHF 5.0% pet | 0 | 0 | 0 | – |
| DEHF 0.50% pet | 0 | 0 | 0 | – |
| Dimethyl fumarate 0.10% pet | 1 | 1 | 0 | – |
Results shown for all participants, for patients with eczema symptoms, for patients with hand eczema (HE), for patients with other eczema only, and for patients with other eczema localisation only.
Carpet 1: From Bank of Greenland, tested with and without glue (ethanol extract).
Carpet 2: From Bank of Greenland (ethanol extract).
Carpet 3: From telecom workplace, location 1 (ethanol extract).
Carpet 4: From telecom workplace, location 2 (ethanol extract).
BIT: 1,2-Benzisothiazol-3(2H)-one; MI/MCI: 2-methyl-4-isothiazoline-3-one and 5-chloro-2-methyl-4-isothiazoline-3-one (Kathon CG); MI: 2-methyl-4-isothiazoline-3-one; DEHF: bis(2-ethylhexyl) fumarate.